ethyl 3-(2-hydroxy-4-methoxyphenyl)propanoate | 20921-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: ethyl 3-(2-hydroxy-4-methoxyphenyl)propanoate
• 英文别名: Ethyl 3-(2-hydroxy-4-methoxyphenyl)propionate
• CAS: 20921-14-6
• 化学式: C₁₂H₁₆O₄
• 分子量: 224.257
• InChiKey: CYGMGJTWPDEBBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  347.3±27.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(2-hydroxy-4-methoxyphenyl)propanoate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 β-(2-Hydroxy-4-methoxy-phenyl)-propionsaeure
  参考文献：
  名称：

  通过Ir催化的CH酰胺化反应（涉及Ir-硝烯中间体）合成内酰胺。

  摘要：

  我们已经开发了一种通过sp3 CH键的酰胺化或Ir-nitrene中间体亲电取代芳烃来合成五元和六元内酰胺的策略。通过在二氯甲烷或六氟-2-丙醇中使用易于获得的铱催化剂，以高至优异的产率和高选择性合成了多种内酰胺。

  DOI：

  10.1021/acs.joc.0c00157
• 作为产物：
  描述：

  2-羟基-4-甲氧基苯甲醛 在 palladium on activated carbon 、 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 ethyl 3-(2-hydroxy-4-methoxyphenyl)propanoate
  参考文献：
  名称：

  通过Ir催化的CH酰胺化反应（涉及Ir-硝烯中间体）合成内酰胺。

  摘要：

  我们已经开发了一种通过sp3 CH键的酰胺化或Ir-nitrene中间体亲电取代芳烃来合成五元和六元内酰胺的策略。通过在二氯甲烷或六氟-2-丙醇中使用易于获得的铱催化剂，以高至优异的产率和高选择性合成了多种内酰胺。

  DOI：

  10.1021/acs.joc.0c00157

文献信息

• [EN] 1,2-AZOLE DERIVATIVES WITH HYPOGLYSEMIC AND HYPOLIPIDEMIC ACTIVITY<br/>[FR] DERIVES 1,2-AZOLE PRESENTANT UNE ACTIVITE HYPOGLYCEMIQUE ET HYPOLIPIDEMIQUE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2003099793A1

  公开（公告）日：2003-12-04

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的结构式（1），其中环A是一个环，可选地具有1到3个取代基；环B是一个1,2-唑环，可能进一步具有1到3个取代基；Xa、Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是一个具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个可能进一步具有1到3个取代基的单环芳香环；R代表-OR4（R4是氢原子或可选择地取代的碳氢基团）等，或其盐或前药，可用作糖尿病的预防或治疗剂等。
• Ruthenium-Catalyzed Intramolecular Arene C(sp²)–H Amidation for Synthesis of 3,4-Dihydroquinolin-2(1<i>H</i>)-ones
  作者：Wenlong Sun、Cho-Hon Ling、Chi-Ming Au、Wing-Yiu Yu

  DOI：10.1021/acs.orglett.1c00781

  日期：2021.5.7

  2-dioxazol-5-ones to form dihydroquinoline-2-ones in excellent yields with excellent regioselectivity via a formal intramolecular arene C(sp2)–H amidation. The reactions of the 2- and 4-substituted aryl dioxazolones proceeds initially through spirolactamization via electrophilic amidation at the arene site, which is para or ortho to the substituent. A Hammett correlation study showed that the spirolactamization

  我们报道了[Ru（对-cymene）（l-脯氨酸）Cl]（[Ru1]）催化的1,4,2-二恶唑-5-酮环化反应形成二氢喹啉-2-酮，具有优异的产率和极好的区域选择性通过正式的分子内芳烃C（sp 2）–H酰胺化。2-和4-取代的芳基二恶唑酮的反应首先通过在芳烃位点上的亲电酰胺化的螺内酰胺化进行，该芳烃位点对取代基是对位的或邻位的。Hammett相关性研究表明，螺内酰胺化可能是由于对苯丙氨酸的亲电子亚硝基化合物攻击而发生的，其特征是-0.73的负ρ值。
• A Simple and Broadly Applicable C−N Bond Forming Dearomatization Protocol Enabled by Bifunctional Amino Reagents
  作者：Xiaofeng Ma、Joshua J. Farndon、Tom A. Young、Natalie Fey、John F. Bower

  DOI：10.1002/anie.201708176

  日期：2017.11.13

  A C-N bond forming dearomatization protocol with broad scope is outlined. Specifically, bifunctional amino reagents are used for sequential nucleophilic and electrophilic C-N bond formations, with the latter effecting the key dearomatization step. Using this approach, γ-arylated alcohols are converted to a wide range of differentially protected spirocyclic pyrrolidines in just two or three steps.

  概述了具有广泛范围的 CN 键形成脱芳构化方案。具体来说，双功能氨基试剂用于顺序亲核和亲电CN键形成，后者影响关键的脱芳构化步骤。使用这种方法，只需两到三个步骤即可将 γ-芳基化醇转化为各种差异保护的螺环吡咯烷。
• 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
  申请人：Maekawa Tsuyoshi

  公开号：US20060148858A1

  公开（公告）日：2006-07-06

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents —OR 4 (R 4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的化学式为(1)，其中环A是一个环，可以有1到3个取代基；环B是一个1,2-咪唑环，可以进一步具有1到3个取代基；Xa，Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个都是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个单环芳香环，可以进一步具有1到3个取代基；R代表-OR4（R4是氢原子或可选的取代烃基）等，或其盐或前药，可用作预防或治疗糖尿病等的药物。
• Prenylcoumarin with Rev-export inhibitory activity from Cnidii Monnieris Fructus
  作者：Satoru Tamura、Toshiaki Fujitani、Masafumi Kaneko、Nobutoshi Murakami

  DOI：10.1016/j.bmcl.2010.04.081

  日期：2010.6

  By use of the fission yeast expressing the model fusion protein comprised of GST, SV40 T antigen NLS, GFP, and Rev-NES in the bioassay, the prenylcoumarin osthol (1) was disclosed as the new Rev-export inhibitor from the MeOH extract of Cnidii Monnieris Fructus. Furthermore, 1 was also found to inhibit export the genuine Rev in HeLa cells by indirect fluorescent antibody technique. By the competitive experiment using the biotinylated probe 3, osthol (1) was revealed to inhibit nuclear export of Rev through a NES non-antagonistic mode. Structure-activity relationship analysis of several analogs of 1 clarified that both prenyl side chain and double bond adjacent to the lactone carbonyl residue play an important role in the Rev-export inhibitory potency of 1. (C) 2010 Elsevier Ltd. All rights reserved.